SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-21-061032
Filing Date
2021-11-22
Accepted
2021-11-22 09:00:29
Documents
14
Period of Report
2021-11-22
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea151173-8k_lantern.htm   iXBRL 8-K 26840
2 PRESS RELEASE DATED NOVEMBER 22, 2021 ANNOUNCING SHARE REPURCHASE PROGRAM TO BE ea151173ex99-1_lantern.htm EX-99.1 14173
6 GRAPHIC ex99-1_001.jpg GRAPHIC 2691
  Complete submission text file 0001213900-21-061032.txt   224021

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE ltrn-20211122.xsd EX-101.SCH 3040
4 XBRL LABEL FILE ltrn-20211122_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE ltrn-20211122_pre.xml EX-101.PRE 22369
7 EXTRACTED XBRL INSTANCE DOCUMENT ea151173-8k_lantern_htm.xml XML 3702
Mailing Address 1920 MCKINNEY AVENUE 7TH FLOOR DALLAS TX 75201
Business Address 1920 MCKINNEY AVENUE 7TH FLOOR DALLAS TX 75201 972-277-1136
Lantern Pharma Inc. (Filer) CIK: 0001763950 (see all company filings)

IRS No.: 463973463 | State of Incorp.: TX | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39318 | Film No.: 211430315
SIC: 2834 Pharmaceutical Preparations